Biblio Discovery — Demo Discovery Service

5 results for "Manvendra Kumar"

Showing 1–5 · 1.61 seconds · RSS

  1. Journal Article Full text

    Understanding Inflammatory Responses in the Manifestation of Prothrombotic Phenotypes

    Chanchal, Shankar; Mishra, Aastha; Singh, Manvendra Kumar et al.

    Front Cell Dev Biol · 2020 · English · PubMed Central

    Inflammasome complex is a multimeric protein comprising of upstream sensor protein of nucleotide-binding oligomerization domain (NOD)-like receptor family. It has an adaptor protein apoptosis-associated speck-like protein and downstream effector cysteine protease procaspase-1. Activation of…

    Also available at: DOAJ

  2. Journal Article Full text

    Intermixing of Unoccupied States of Metal Phthalocyanine Chains Assembled on Au(110)

    Abhishek Kumar; Maria Grazia Betti; Carlo Mariani et al.

    Nanomaterials, Vol. 14 No. 2 · 2024 · English · DOAJ Scopus

    A detailed inverse photoemission study unveils the unoccupied electronic structure induced by the adsorption of CuPc and CoPc phthalocyanines on Au(110) reconstructed channels. The different behavior in the two systems is related to the different intermixing of orbitals with the underlying gold…

  3. Journal Article Full text

    Design and Synthesis of Non-Covalent Imidazo[1,2-a]quinoxaline-Based Inhibitors of EGFR and Their Anti-Cancer Assessment

    Manvendra Kumar; Gaurav Joshi; Sahil Arora et al.

    Molecules, Vol. 26 No. 5 · 2021 · English · DOAJ Scopus

    A series of 30 non-covalent imidazo[1,2-a]quinoxaline-based inhibitors of epidermal growth factor receptor (EGFR) were designed and synthesized. EGFR inhibitory assessment (against wild type) data of compounds revealed 6b, 7h, 7j, 9a and 9c as potent EGFRWT inhibitors with IC50 values of 211.22…

  4. Journal Article Full text

    In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice

    Zahid Rafiq Bhat; Manvendra Kumar; Nisha Sharma et al.

    Molecules, Vol. 27 No. 17 · 2022 · English · DOAJ Scopus

    Tyrosine kinase inhibitors are validated therapeutic agents against EGFR-mutated non-small cell lung cancer (NSCLC). However, the associated critical side effects of these agents are inevitable, demanding more specific and efficient targeting agents. Recently, we have developed and reported a…